Compare LGIH & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | MPLT |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 984.3M | 811.3M |
| IPO Year | 2013 | N/A |
| Metric | LGIH | MPLT |
|---|---|---|
| Price | $45.62 | $29.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $75.90 | $32.67 |
| AVG Volume (30 Days) | ★ 398.7K | 285.9K |
| Earning Date | 04-28-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $1,705,504,000.00 | N/A |
| Revenue This Year | $2.32 | N/A |
| Revenue Next Year | $17.94 | N/A |
| P/E Ratio | $14.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.55 | $12.24 |
| 52 Week High | $69.42 | $33.28 |
| Indicator | LGIH | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 59.30 | 62.94 |
| Support Level | $41.82 | $15.34 |
| Resistance Level | $48.83 | N/A |
| Average True Range (ATR) | 2.26 | 2.82 |
| MACD | 1.05 | 0.23 |
| Stochastic Oscillator | 77.50 | 67.50 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.